Asylia Therapeutics, established August 6, 2019, is a private, development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, which collectively impact millions of Americans annually. The company’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has, to date, produced remarkable anti-tumor responses across a spectrum of well established cancer models.